These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37813779)

  • 1. Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162-170.
    Margalit O; Harmsen WS; Shacham-Shmueli E; Voss MM; Boursi B; Wagner AD; Cohen R; Olswold CL; Saltz LB; Goldstein DA; Hurwitz H; Tebbutt NC; Kabbinavar FF; Adams RA; Chibaudel B; Grothey A; Yoshino T; Zalcberg J; de Gramont A; Shi Q; Lenz HJ
    Eur J Cancer; 2023 Nov; 194():113339. PubMed ID: 37813779
    [No Abstract]   [Full Text] [Related]  

  • 2. [The cost study of first- line treatment of metastatic colorectal carcinoma with bevacizumab- containing regimen in the Czech Republic].
    Hradecká I; Ríhová B; Horová R; Demlová R
    Klin Onkol; 2014; 27(4):255-60. PubMed ID: 25115714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Integration Process of Clinical Trial Data in ARCAD-Asia].
    Bando H; Takeda Y; Misumi T; Suzuki M; Wakabayashi M; Ohtsu A; Yoshino T
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1021-1026. PubMed ID: 38035827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
    Tournigand C; Chibaudel B; Samson B; Scheithauer W; Vernerey D; Mésange P; Lledo G; Viret F; Ramée JF; Tubiana-Mathieu N; Dauba J; Dupuis O; Rinaldi Y; Mabro M; Aucoin N; Latreille J; Bonnetain F; Louvet C; Larsen AK; André T; de Gramont A
    Lancet Oncol; 2015 Nov; 16(15):1493-1505. PubMed ID: 26474518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009).
    Zinser-Sierra JW; Rodríguez-Ramírez S; Villalobos-Valencia R; Ramírez-Márquez M
    Drugs R D; 2011; 11(2):101-11. PubMed ID: 21679003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corrigendum to "RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody" [Eur. J. Radiol. 141 (2021) 109823].
    Li L; Xu Y; Yang Y; Ye F; Zhang H; Zhou A; Zhao X
    Eur J Radiol; 2021 Sep; 142():109897. PubMed ID: 34371308
    [No Abstract]   [Full Text] [Related]  

  • 8. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
    Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
    Tomasello G; Petrelli F; Ghidini M; Russo A; Passalacqua R; Barni S
    JAMA Oncol; 2017 Jul; 3(7):e170278. PubMed ID: 28542671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer.
    Miyamoto Y; Oki E; Emi Y; Tokunaga S; Shimokawa M; Ogata Y; Akagi Y; Sakamoto Y; Tanaka T; Saeki H; Maehara Y; Baba H
    Anticancer Res; 2018 Jan; 38(1):491-499. PubMed ID: 29277814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis.
    Cai J; Ma H; Huang F; Zhu D; Bi J; Ke Y; Zhang T
    World J Surg Oncol; 2013 Nov; 11():306. PubMed ID: 24283603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
    van Dijk E; van Werkhoven E; Asher R; Mooi JK; Espinoza D; van Essen HF; van Tinteren H; van Grieken NCT; Punt CJA; Tebbutt NC; Ylstra B
    Int J Cancer; 2022 Oct; 151(7):1166-1174. PubMed ID: 35489024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer.
    Khan SA; Zeng Z; Shia J; Paty PB
    Pathol Oncol Res; 2017 Jul; 23(3):673-677. PubMed ID: 28025786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
    Bates DO; Catalano PJ; Symonds KE; Varey AH; Ramani P; O'Dwyer PJ; Giantonio BJ; Meropol NJ; Benson AB; Harper SJ
    Clin Cancer Res; 2012 Nov; 18(22):6384-91. PubMed ID: 23104894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.
    Voutsadakis IA
    Curr Oncol; 2023 May; 30(6):5227-5239. PubMed ID: 37366880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of novel PPP1R15A and proposed ANXA11 single nucleotide polymorphisms as predictive markers for bevacizumab regimen in metastatic colorectal cancer.
    Roh SA; Park IJ; Yoon YS; Kwon YH; Chung JH; Kim TW; Cho DH; Lim BH; Kim SK; Kim SY; Kim YS; Kim JC
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1705-14. PubMed ID: 27177629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma.
    Tatlı AM; Coşkun HŞ; Uysal M; Arslan D; Sezgin Göksu S; Güenay Gündüz S; Cakal S; Bozcuk HŞ; Savaş B
    Int J Clin Exp Med; 2014; 7(8):2191-6. PubMed ID: 25232406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
    Lombardi P; Rossini D; Crespi V; Germani MM; Bergamo F; Pietrantonio F; Santini D; Allegrini G; Daniel F; Pagani F; Antoniotti C; Zaniboni A; Conca V; Latiano TP; Boccaccino A; Passardi A; Tamburini E; Masi G; Di Maio M; Cremolini C
    Cancer Treat Rev; 2022 Feb; 103():102326. PubMed ID: 35016085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.